Inhaled corticosteroids may have a protective effect against coronavirus infection

Main Article Content

Alicia Armentia
Sara Fernández Cortés
Angela Moro Simón
Blanca Martín-Armentia
Sara Martín-Armentia
Daniel Ramos Pollo
Juan Claudio Navarro Cañadas
Javier Visa Caño
Álvaro Sanz Rubiales
Joaquín Rodriguez Fra
Sara García Vaquero
Marta Cano Pazos
Jesús Galán de la Calle
Edgardo Raul Lowell
Cristina Crespo Soto
Carmen Sánchez Toledano
Aurora Sacristán Salgado


Allergy, coronavirus, nursing home, asthma severe, corticosteroids, COVID, telemedicine., Th2 cell immunity, coronavirus infection


Background: Spain has been severely affected by the COVID-19 epidemic, with 195,944 persons infected and 20,453 deaths at the time of writing. Older people with respiratory or cardiac conditions are most at risk.

Objective: The aim was to compare respiratory symptoms in nursing home residents and patients with uncontrolled asthma, who are considered vulnerable to COVID-19.

Methods: We studied 134 nursing home residents and 139 patients with uncontrolled asthma, groups vulnerable to COVID-19. Demographic characteristics, clinical manifestations, outcomes, key laboratory results, and radiological images were collected from medical records. COVID-19 infection was detected by polymerase chain reaction (PCR).

Results: Thirteen (9.3%) patients with uncontrolled asthma, all receiving inhaled corticosteroids were infected by COVID-19. Eighty (60%) nursing home residents were infected; only 28, all of whom had received inhaled corticosteroids, had a good prognosis.

Conclusions: Early treatment with inhaled corticosteroids may be helpful in COVID-19 infection. Persons with an allergy might have some protective mechanisms against coronavirus.

Abstract 38 | PDF Downloads 38 XML Downloads 0 HTML Downloads 0


1. World Health Organization Coronavirus disease 2019 (COVID-19) Situation Report. Available from: default-source/coronaviruse/20200312-sitrep-52-covid-19.pdf? sfvrsn=e2bfc9c0_2.

2. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239– 1242.

3. Korean Society of Infectious Diseases. Report on the epidemiological features of coronavirus disease 2019 (COVID-10) outbreak in the Republic of Korea from January 19 to March 2, 2020. J Korean Med Sci. 2020;35(10):e112. jkms.2020.35.e112

4. Shaker MS, Oppenheimer J, Grayson M, Stukus D, Hartog N, Hsieh E, et al. COVID- 19: pandemic contingency planning for the Allergy and Immunology Clinic. J Allergy Clin Immunol Pract. 2020;8:1477. e5–1488.e5.

5. Jiang X, Hou X, Tang L, Jiang Y, Ma G, Li Y. A phase trial of the oral Lactobacillus casei vaccine polarizes Th2 cell immunity against transmissible gastroenteritis coronavirus infection. App Microbiol Biotechnol. 2016;100:7457–7469. https://doi. org/10.1007/s00253-016-7424-9

6. Dong X, Cao YY, Lu XX, Zhang JJ, Du H, Yan Yq, et al. Eleven faces of coronavirus disease 2019. Allergy. 2020;75(7):1699– 1709.

7. Zhang JJ, Dong X, Cao YY, Yuan YD, Yang YB, Yan UQ, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China, Allergy. 2020;75(7):1730–1741. https://

8. Song YG, Shin HS. COVID-19. A clinical syndrome manifest-ing as hypersensitivity pneumonitis. Infect Chemother. 2020;52(1):110–112.

9. Zheng C, Wang J, Ghuo H, Lu Z, Ma Y, Zhu X, et al. Risk adapted treatment strategy for COVID-10 patients. Int J Infect Dis. 2020;pii:S1201-9712(20)30179-X. ijid.2020.03.047

10. Ye Z, Wang Y, Colunga-Lozano LE, Prasad M, Tangamprnsuksan W, Rochwerg B, Yao L, Motaghi S, Couban RJ, Ghadimi M, Bala MM, Gomaa H, Fang F, Xiao Y, Guyatt GH. Efficacy and safety of corticosteroids in COVID-19 bases on evidence for COVID-19 other coronavirus infections, influenza, community-acquired pneumonia and acute respiratory distress syndrome: a systematic review and meta-analysis. CMAJ 2020;1962:756-67 200645